Full-Time

Director – Global Analytical Sciences and Technology

Asat, Drug Substance

Posted on 11/19/2024

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Compensation Overview

$220k - $236kAnnually

Senior, Expert

Remote in USA

Category
Bioinformatics
Computational Biology
Genomics
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Degree(s) in Chemical or Biochemical Engineering, Chemistry, Biochemistry, or related discipline with a minimum of 12+ years of relevant experience for Ph.D., 15+ years for M.S./M.A., or 20+ years for B.S./B.A.
  • Extensive experience in analytical method development, validation, method transfer, commercial launch, and analytical lifecycle management of glycoconjugate vaccines preferred.
  • Demonstrated ability to coordinate CDMO activities and direct experience with directing outsourced assay development, stability, and quality control in support of CMC activities.
  • Leadership experience in analytical development, QC, ASAT or MSAT in supervisory and/or matrixed team roles.
  • Able to leverage deep technical knowledge in a collaborative manner to establish strategic plans and achieve collective goals.
  • Excellent organization, problem solving and strategic planning skills.
  • Highly skilled in both verbal and written communication with the ability to interact effectively with people of diverse backgrounds and perspectives.
  • Proactively recognizes needs and potential challenges and directs activities to implement effective solutions.
  • The ability to seek and analyze data from a variety of sources to support decisions and to align others with the organization's overall strategy.
  • An entrepreneurial and creative approach to developing new, innovative ideas that will stretch the organization and push the boundaries within the industry.
Responsibilities
  • Provide technical and scientific advice for internal and external stakeholders in support of the successful execution of launch plans and post-launch commercial activities.
  • Manage and support the analytical control strategy with advanced state-of-the-art analytical equipment and technologies and routine trouble shooting.
  • Develop and validate new analytical techniques and methods.
  • Provide leadership for analytical validation and comparability activities.
  • Provide analytical support activities related to method development and qualification/validation, product characterization, and comparability assessment for multiple programs.
  • Provide technical support for complex analytical challenges.
  • Tech-transfer new technologies - support technical transfers and integration of new technologies.
  • Support of our internal and external manufacturing network, including materials management and data analytics.
  • Engage in technical reviewing and authoring of regulatory filings and responding to questions received from health authorities.
  • Serve as a thought partner with Regulatory, CMC, Quality, Supply Chain, Sourcing, and Process Engineering colleagues.
  • Collaboration with cross-functional teams across the internal and external network to drive the successful development and commercial launch of pipeline products.
  • Effectively and efficiently communicate process performance to key stakeholders (internal-facing and external-facing).
  • Contribute as Global ASAT lead and as member of the Global Manufacturing Operations, with an aim to ensure effective and efficient delivery of our life-enhancing therapies to our patients.
  • Lead matrixed teams focused on analytical lifecycle of test methods for commercialization with an aim to ensure effective and efficient delivery of our life-enhancing therapies to our patients.
Desired Qualifications
  • Extensive experience in analytical method development, validation, method transfer, commercial launch, and analytical lifecycle management of glycoconjugate vaccines preferred.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. This method sets them apart from traditional cell-based vaccine production. The company's goal is to develop broad-spectrum vaccines that can significantly reduce the impact of bacterial diseases on global health.

Company Size

201-500

Company Stage

IPO

Headquarters

Foster City, California

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA Breakthrough Therapy designation for VAX-24 may accelerate its market entry.
  • Global pneumococcal vaccines market is projected to grow at a CAGR of 5.6% until 2030.
  • Recent $1.5 billion public offering strengthens Vaxcyte's financial position for future developments.

What critics are saying

  • Competition from mRNA technology developers like Moderna and BioNTech is intense.
  • Potential regulatory delays could impact Vaxcyte's clinical trial timelines.
  • Intellectual property disputes may arise over cell-free protein synthesis technology.

What makes Vaxcyte unique

  • Vaxcyte uses a proprietary cell-free protein synthesis platform, XpressCF™, for vaccine development.
  • Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae bacteria.
  • Vaxcyte focuses on broad-spectrum vaccines for bacterial infections, unlike traditional methods.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

1%

2 year growth

0%
MarketBeat
Oct 5th, 2024
Clearbridge Investments LLC Makes New $14.06 Million Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

Clearbridge Investments LLC makes new $14.06 million investment in Vaxcyte, Inc. (NASDAQ:PCVX).

Bizjournals
Sep 20th, 2024
Winner, Public Company, Small: Andrew Guggenhime, Vaxcyte Inc.

In the early weeks of the Covid-19 pandemic, Andrew Guggenhime joined San Carlos-based Vaxcyte Inc. as chief financial officer and chief operating officer, drawn by the company's mission to develop vaccines to prevent and treat infectious bacterial diseases.

Yahoo Finance
Sep 9th, 2024
Vaxcyte Announces Pricing of $1.3 Billion Public Offering

SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock

Vaxcyte
Sep 6th, 2024
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte announces closing of $1.5 billion public offering including full exercise of underwriters' option to purchase additional shares.

GlobeNewswire
Sep 5th, 2024
Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Vaxcyte announces pricing of $1.3 billion public offering.

INACTIVE